D I S S E C T I N G B U S I N E S S using its proprietary chelator technology platform that enables radiolabelling of targeting moieties against cancers with therapeutic isotopes of lead( Pb-212) or diagnostic isotopes such as Ga-68 for high-resolution imaging of uptake or Pb-203 for retention of uptake. The company has also entered into exclusive licensing and patent agreements with academic institutions to broaden its alpha-emitting radiopharmaceutical platform capabilities.
• PRECIRIX, founded as a spinoff from Vrije Universiteit Brussel( VUB), is designing and developing radiopharmaceutical theranostics using camelid single-domain antibodies( sdAb) labelled with radiometals against multiple targets. The company ' s lead programme, which targets fibroblast activation protein( FAP), could be a best-in-class alpha-emitting targeted radiotherapy against FAP and has been designed to address FAP-positive tumours.
Notable developments shaping the RLT field include high-profile acquisitions Ω – such as Bristol Myers Squibb ' s US $ 4.1 billion purchase of RayzeBio and AstraZeneca ' s US $ 2.4 billion acquisition of Fusion Pharmaceuticals – as well as blockbuster therapies like Novartis ' PLUVICTO and LUTATHERA, which have paved the way for broader adoption.
As the global radiopharmaceutical market is projected to surpass US $ 13 billion within the next decade, the companies featured in this report are well-positioned to lead the next wave of therapeutic innovation.
To download the full report or learn more, visit here. �
www. intelligenthealth. tech 31